Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

Documenti analoghi

• Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
  di: Mickisch, G, et al.
  Pubblicazione: (2010)
• Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
  di: Charbonneau, C, et al.
  Pubblicazione: (2010)
• Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
  di: Mickisch, G H J, et al.
  Pubblicazione: (2010)
• Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
  di: Mickisch, Gerald HJ, et al.
  Pubblicazione: (2011)
• Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
  di: Thompson Coon, J S, et al.
  Pubblicazione: (2009)